Lacoin L, et al. - Analysts depict the changes in prescribing of oral anticoagulant (AC) and antiplatelet (AP) agents in patients with non-valvular atrial fibrillation (NVAF) in the UK and aim to recognize the attributes related to deviation from guideline-based recommendations. Between April 2012 and January 2016, major improvements in the antithrombotic (AT) management of patients with NVAF for stroke prevention in the UK was observed. Despite this, almost 20% of at-risk patients still received AP alone and over 15% were on no AT agents in January 2016.